General Principles in Pharmacology

GENERAL PRINCIPLES http://crisbertcualteros.page.tl

GENERAL PRINCIPLES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PHARMACOKINETICS ,[object Object],[object Object],[object Object],[object Object]

FACTORS AFFECTING ABSORPTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORS AFFECTING ABSORPTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DEGREE OF IONIZATION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FORMULA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

EX OF WEAK ACID WITH PKA OF 8 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

EXAMPLE OF A WEAK BASE WITH PKA OF 8 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ROUTES OF ADMINISTRATION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DISTRIBUTION OF DRUGS ,[object Object],[object Object],[object Object],[object Object],[object Object]

METABOLISM/ BIOTRANSFORMATION OF DRUGS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PHASE I METABOLISM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PHASE I METABOLISM ,[object Object],[object Object],[object Object],[object Object],[object Object]

PHASE II METABOLISM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DRUG METABOLISM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DRUG METABOLISM ,[object Object],[object Object],[object Object],[object Object],[object Object]

EXCRETION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

QUANTITATIVE PHARMACOKINETICS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DOSAGE REGIMEN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PHARMACODYNAMICS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PHARMACODYNAMICS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TARGET FOR DRUG ACTION ,[object Object],[object Object],[object Object],[object Object]

RECEPTORS Agonist Antagonist Beta adrenoreceptor Norepi- nephrine Propranolol Opiate (mu) Morphine Naloxone Dopamine (D2) Dopamine Bromocrip- tine Chlorpro- mazine Insulin insulin None known Estrogen receptors Ethinyl- estradiol Tamoxifen

ENZYMES INHIBITORS FALSE SUBSTRATE Cyclooxy- genase Aspirin Carbonic Anhydrase Acetazola- Mide Dihydrofolate reductase trimetoprin Monoamine oxidase B Selegiline Angiotensin convering enzymes Captopril

ION CHANNELS BLOCKERS MODULATORS Renal tubule Sodium channels Amiloride Aldosterone ATP sensitive K + channels ATP Cromokalin sulfonylureas GABA gated chloride channels Picrotoxin Benzodiazepines Voltage gated Ca ++ channels Divalent cations Beta-adrenoreceptor agonists

CARRIERS INHIBITORS FALSE SUBSTRATE Na + K + Cl co transporter Loop diuretics Na + K + pump Cardiac glycosides Proton pump Omeprazole Weak acid carrier(renal tubule) Probenecid

OVERVIEW OF PRODUCT DEVELOPMENT Lead Compound Efficacy Selectivity Mechanism Phase 1 Phase 2 Phase 3 Drug metabolism, safety assessment Phase 4 In vitro studies Animal Studies Clinical Testing Marketing 0 2 4 8 – 9 20 YEARS

Thank You! ,[object Object],[object Object]

General Principles in Pharmacology

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie General Principles in Pharmacology

Ähnlich wie General Principles in Pharmacology (20)

Mehr von DJ CrissCross

Mehr von DJ CrissCross (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

General Principles in Pharmacology